FTC questions drugmakers’ patents, including for Ozempic
In a recent move to combat alleged patent abuse by pharmaceutical companies, the Federal Trade Commission (FTC) has challenged hundreds of “junk” patents held by companies for 20 brand-name drugs, including Novo Nordisk’s blockbuster diabetes … Read more